Hot Trading Industry Trends and Related Hong Kong Stocks

CRO / Innovative Drug Sector Continues Strong Performance

$WUXI APPTEC(02359.HK) reported doubled interim profits, igniting the pharmaceutical outsourcing sector. Besides the positive interim results from WuXi AppTec, other pharmaceutical firms' mid-year performance forecasts indicate a steady recovery trend for CRO and CDMO companies.

Institutions suggest the pharmaceutical industry has reached a turning point. Zhongtai Securities pointed out in its latest research report that global demand is improving, and financing expectations are optimistic. Domestic reserve requirement ratio cuts, interest rate reductions, the completion of large BD deals for innovative drugs, and improved financing conditions are expected to boost domestic investment and CRO demand.

CRO Concept Stocks: $WUXI APPTEC(02359.HK), $WUXI BIO(02269.HK), $TIGERMED(03347.HK), $JOINN(06127.HK), $PHARMARON(03759.HK);

Innovative Drug Concept Stocks: $HENGRUI PHARMA(01276.HK), $BEONE MEDICINES(06160.HK), $HANSOH PHARMA(03692.HK), $INNOVENT BIO(01801.HK), $SBP GROUP(01177.HK), $AKESO(09926.HK), $CSPC PHARMA(01093.HK), $3SBIO(01530.HK), $ZAI LAB(09688.HK), $SIMCERE PHARMA(02096.HK);

Biotech B-Shares: $SKB BIO(06990.HK), $ASCENTAGE(06855.HK), $EVEREST MED(01952.HK), $KEYMED BIO-B(02162.HK), $LEPU BIO(02157.HK), $CARSGEN-B(02171.HK)

Today's Hong Kong Tech Stocks Declined: $XIAOMI-W(01810.HK), $TENCENT(00700.HK), $BILIBILI-W(09626.HK), $KUAISHOU-W(01024.HK), $NTES(09999.HK), $BABA-W(09988.HK), $MEITUAN(03690.HK)

Among them, $XIAOMI-W(01810.HK) fell for three consecutive days, hitting a one-month low.